Abstract
Malignant mesothelioma (MM) generally occurs as a pleural tumour, related to the inhalation of asbestos fibres. It is highly aggressive and largely unresponsive to treatment. The incidence of MM is particularly high in Western Australia because of the extensive blue asbestos mining operations that occurred in the north of the state until 1966. MM is unusual in that mutations in the tumour suppressor gene p53 are rarely observed, whilst over-expression of p53 protein is common. As the level of antibodies directed against p53 is thought to be of prognostic value in some cancers and as MM is known to be immunogenic, we studied a cohort of Western Australian patients to determine the prevalence of anti-p53 antibodies and their value as diagnostic markers or prognostic indicators. 6/88 (7%) of patients had high titres (>2 SD above the mean of controls) of anti-p53 antibodies. There was no correlation between antibody titre and survival. Although 3/38 (8%) of sera obtained from patients exposed to asbestos but prior to a diagnosis of MM contained antibodies, the same proportion of sera obtained from patients exposed to asbestos but who remained disease free also contained antibodies (2/40; 8%). Sera collected sequentially demonstrated a profound temporal stability in the titre of anti-p53 antibodies in patients with MM throughout the course of their illness. These results show that anti-p53 antibodies are observed only at a low frequency in the sera of MM patients and where they do occur, their elicitation is an early event that may be unrelated to antigen load. The occurrence of anti-p53 antibodies does not serve as either a useful prognostic or diagnostic indicator in MM. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Andersson M, Wallin H, Jonsson M, Nielsen LL, Visfeldt J, Vyberg M, Bennett WP, De Benedetti VM, Travis LB and Storm HH (1995) Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status . Int J Cancer 63: 330–336
Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA and Bunting PS (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58: 480–487
Ashcroft M and Vousden KH (1999) Regulation of p53 stability [Review]. Oncogene 18: 7637–7643
Brass N, Racz A, Bauer C, Heckel D, Sybrecht G and Meese E (1999) Role of amplified genes in the production of autoantibodies. Blood 93: 2158–2166
Carbone M, Fisher S, Powers A, Pass HI and Rizzo P (1999) New molecular and epidemiological issues in mesothelioma: Role of SV40. J Cell Physiol 180: 167–172
Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M and Chen W (1995) Immunity to oncogenic proteins [Review]. Immunological Reviews 145: 33–59
Davidson JA, Musk AW, Wood BR, Morey S, Ilton M, Yu LL, Drury P, Shilkin K and Robinson BWS (1998) Intralesional cytokine therapy in cancer – a pilot study of GM-CSF infusion in mesothelioma. Journal of Immunotherapy 21: 389–398
de Klerk N, Musk AW, Ambrosini GL, Eccles JL, Hansen J, Olsen N, Watts VL, Lund HG, Pang SC, Beilby J and Hobbs MS (1998) Vitamin A and cancer prevention II: comparison of the effects of retinol and beta-carotene. Int J Cancer 75: 362–367
Esposito V, Baldi A, De LA, Claudio PP, Signoriello G, Bolognese A, Centonze P, Giordano GG, Caputi M, Baldi F and Giordano A (1997) p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. Anticancer Res 17: 733–736
Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Gagetti O, Bevilacqua G and Genazzani AR (1999) Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecologic Oncology 72: 76–81
Gansauge S, Gansauge F, Negri G, Galle P, Muller J, Nussler AK, Poch B and Beger HG (1996) The role of anti-p53-autoantibodies in pancreatic disorders. Int J Pancreatol 19: 171–178
Gonin S, Diaz-Latoud C, Richard MJ, Ursini MV, Imbo A, Manero F and Arrigo AP (1999) p53/T-antigen complex disruption in T-antigen transformed NIH3T3 fibroblasts exposed to oxidative stress: correlation with the appearance of a Fas/APO-1/CD95 dependent, caspase independent, necrotic pathway. Oncogene 18: 8011–8023
Gottschlich S, Folz BJ, Goeroegh T, Lippert BM, Maass JD and Werner JA (1999) A new prognostic indicator for head and neck cancer – p53 serum antibodies?. Anticancer Research 19: 2703–2705
Hammel P, Leroy-Viard K, Chaumette MT, Villaudy J, Falzone MC, Rouillard D, Hamelin R, Boissier B and Remvikos Y (1999) Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer 81: 712–718
Lai CL, Tsai CM, Tsai TT, Kuo BIT, Chang KT, Fu HT, Perng RP and Chen JY (1998) Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res 4: 3025–3030
Lang C, Unteregger G, Kartarius S, Gunther J, Bonkhoff H, Montenarh M and Zwergel T (1998) p53 autoantibodies in patients with urological tumours. Brit J Urol 82: 721–725
Lechner JF, Tesfaigzi J and Gerwin BI (1997) Oncogenes and tumor-suppressor genes in mesothelioma – a synopsis. Environ Health Perspect 105: 1061–1067
Lee WC and Testa JR (1999) Somatic genetic alterations in human malignant mesothelioma (Review). Int J Oncol 14: 181–188
Lenner P, Wiklund F, Emdin SO, Arnerlov C, Eklund C, Hallmans G, Zentgraf H and Dillner J (1999) Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Brit J Cancer 79: 927–932
Levine AJ (1997) p53, the cellular gatekeeeper for cell growth and division. Cell 88: 323–331
Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP and Soussi T (1995) p53 antibodies in patients with various types of cancer – assay, identification, and characterization. Clini Cancer Res 1: 1463–1469
Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW and Robinson BW (1991) Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 47: 285–290
Mayall FG, Jacobson G and Wilkins R (1999) Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas. J Clin Pathol 52: 291–293
McLaren BR, Haenel T, Stevenson S, Mukherjee S, Robinson BWS and Lake RA (2000) SV40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas. Aust NZJ Med 30: 450–456
Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K and Gerwin BI (1992) p53 and Kirstenras mutations in human mesothelioma cell lines. Cancer Res 52: 2610–2615
Mitsudomi T, Suzuki S, Yatabe Y, Nishio M, Kuwabarn M, Gotoh K, Hatooka S, Shinoda M, Suyama M, Ogawa M, Takahashi T and Ariyoshi Y (1998) Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J Natl Cancer Inst 90: 1563–1568
Mor O, Yaron P, Huszar M, Yellin A, Jakobivitz O, Broksimoni F, Rechavi G and Reichert N (1997) Absence of p53 mutations in malignant mesotheliomas. Am J Resp Cell Mol Biol 16: 9–13
Murthy SS and Testa JR (1999) Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 180: 150–157
Musk AW, Bowman RV, Christmas TI and Robinson BW (1992) Management of malignant mesothelioma. Henderson DW, Shikin KB, Langlois SW, Whitaker D (eds) Malignant Mesothelioma, Hemisphere Publishing Corporation: New York. pp. 293–302
Musk AW, de KN, Ambrosini GL, Eccles JL, Hansen J, Olsen NJ, Watts VL, Lund HG, Pang SC, Beilby J and Hobbs MS (1998) Vitamin A and cancer prevention I: observations in workers previously exposed to asbestos at Wittenoom, Western Australia. Int J Cancer 75: 355–361
Nakajima K, Suzuki T, Shimada H, Hayashi H, Takeda A and Ochiai T (1999) Detection of preoperative serum anti-p53 antibodies in gastric cancer. Tumor Biology 20: 147–152
Ramael M, Lemmens G, Eerdekens C, Buysse C, Deblier I, Jacobs W and van Marck E (1992) Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium. J Pathol 168: 371–375
Robinson C, Robinson BWS and Lake RA (1998) Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer 20: 175–184
Robinson C, Callow M, Stevenson S, Scott B, Robinson BW and Lake RA (2000) Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. Am J Respir Cell Mol Biol 22: 550–556
Saffroy R, Lelong JC, Azoulay D, Salvucci M, Reynes M, Bismuth H, Debuire B and Lemoine A (1999) Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma. British Journal of Cancer 79: 604–610
Schneider J, Presek P, Braun A, Bauer P, Konietzko N, Wiesner B and Woitowitz HJ (1999) p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer . British Journal of Cancer 80: 1987–1994
Ungar S, Van de Meeren A, Tammilehto L, Linnainmaa K, Mattson K and Gerwin BI (1996) High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer 74: 1534–1540
Upham J, Musk A, van Hazel G, Byrne M and Robinson B (1993) Interferon alpha and doxorubicin in malignant mesothelioma. Aust NZ J Med 23: 683–687
Vogl FD, Stickeler E, Weyermann M, Kohler T, Grill HJ, Negri G, Kreienberg R and Runnebaum IB (1999) p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology 57: 324–329
Wu CW, Lin YY, Chen GD, Chi CW, Carbone DP and Chen JY (1999) Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade. British Journal of Cancer 80: 483–488
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Creaney, J., McLaren, B., Stevenson, S. et al. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 84, 52–56 (2001). https://doi.org/10.1054/bjoc.2000.1529
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1529
This article is cited by
-
A systematic review of humoral immune responses against tumor antigens
Cancer Immunology, Immunotherapy (2009)